# Phase 1 Esophageal Squamous Cell Carcinoma trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 1 for Esophageal Squamous Cell Carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Esophageal Squamous Cell Carcinoma trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/esophageal-squamous-cell-carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 10, 2026 | NCT07697040 | Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC | Hebei Medical University Fourth Hospital | Phase 1 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697040) |
| March 31, 2026 | NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | IDEAYA Biosciences | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503808) |
| January 22, 2026 | NCT07359417 | MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma | UMC Utrecht | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer, Squamous Cell | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359417) |
| January 5, 2026 | NCT07317609 | Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) | Shanghai Zhongshan Hospital | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07317609) |
| December 16, 2025 | NCT07284186 | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | Plexium, Inc. | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction... | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284186) |
| December 11, 2025 | NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | IDEAYA Biosciences | Phase 1 | Recruiting | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277413) |
| November 14, 2025 | NCT07229313 | A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors | Kivu Bioscience Inc. | Phase 1 | Recruiting | Advance Solid Tumors | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229313) |
| October 15, 2025 | NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell... | EvolveImmune United, Inc | Phase 1 | Recruiting | Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell... | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217171) |
| October 2, 2025 | NCT07203898 | A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma. | Beijing Immupeutics Medicine Technology Limited | Phase 1 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07203898) |
| September 4, 2025 | NCT07154108 | Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer | Sichuan University | Phase 1 | Not yet recruiting | Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154108) |
| July 29, 2025 | NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma... | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090499) |
| July 25, 2025 | NCT07085091 | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | ALX Oncology Inc. | Phase 1 | Recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck... | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085091) |
| October 24, 2024 | NCT06657144 | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | Coherus Oncology, Inc. | Phase 1 | Recruiting | Metastatic Solid Tumor, Advanced Solid Tumor | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06657144) |
| August 9, 2024 | NCT06545331 | Study of XB010 in Subjects With Solid Tumors | Exelixis | Phase 1 | Recruiting | Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC... | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06545331) |
| July 8, 2024 | NCT06491134 | Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma | Hebei Medical University Fourth Hospital | Phase 1 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06491134) |
| February 5, 2024 | NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Recruiting | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung... | 394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06242470) |
| October 16, 2023 | NCT06084481 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving... | AbbVie | Phase 1 | Recruiting | Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma... | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06084481) |
| August 9, 2023 | NCT05984342 | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | Affiliated Cancer Hospital of Shantou University Medical College | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05984342) |
| January 26, 2022 | NCT05208762 | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Recruiting | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma... | 714 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05208762) |
| May 15, 2020 | NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 | Recruiting | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal... | 1,006 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04389632) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| IDEAYA Biosciences | 2 |
| Hebei Medical University Fourth Hospital | 2 |
| [Seagen, a wholly owned subsidiary of Pfizer](https://specstream.ai/data/clinical-trials/company/seagen-a-wholly-owned-subsidiary-of-pfizer) | 2 |
| Affiliated Cancer Hospital of Shantou University Medical College | 1 |
| ALX Oncology Inc. | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| [Exelixis](https://specstream.ai/data/clinical-trials/company/exelixis) | 1 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 1 |
| Plexium, Inc. | 1 |
| Sichuan University | 1 |
| Kivu Bioscience Inc. | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| Coherus Oncology, Inc. | 1 |
| Beijing Immupeutics Medicine Technology Limited | 1 |
| Shanghai Zhongshan Hospital | 1 |
| EvolveImmune United, Inc | 1 |
| UMC Utrecht | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| China | 6 |
| Spain | 5 |
| United Kingdom | 5 |
| South Korea | 3 |
| Australia | 3 |
| Taiwan | 3 |
| Canada | 2 |
| Puerto Rico | 2 |
| France | 2 |
| Japan | 2 |
| Netherlands | 2 |
| Georgia | 1 |
| Switzerland | 1 |
| Belgium | 1 |
| Germany | 1 |
| Italy | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Escrow companies in the United States](https://specstream.ai/data/businesses/escrow-companies/united-states)
- [Aircraft service companies in the United States](https://specstream.ai/data/businesses/aircraft-service-companies/united-states)
- [Pediatric gastroenterology practices in the United States](https://specstream.ai/data/businesses/pediatric-gastroenterology-practices/united-states)
- [Farm insurance companies in the United States](https://specstream.ai/data/businesses/farm-insurance-companies/united-states)
- [Arabian restaurants in the United States](https://specstream.ai/data/businesses/arabian-restaurants/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
